News

Medicare plans must understand the impact of CMS rule change to be prepared for risk adjustment in 2017. Here are 10 tips to better manage the risk adjustment process.

Study: ACOs can be part of the structure to improve outcomes in children with medical complexity.

Here’s what managed healthcare executives should keep an eye on moving into the new year.

FDA issued two important drug warnings this week: one linking certain diabetes medications to bladder cancer and another about the use of general anesthetic and sedation drugs during pregnancy.

Humana and Oak Street Health share the challenges and opportunities of moving away from the fee-for-service model to value-based care.

As 2016 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.

The 21st Century Cures Act, a landmark medical research bill, offers healthcare executives a promising future.

Industry leaders share their sources of inspiration.

Pharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.

In the aftermath of the presidential election, health policy experts have less to go on than they have after any election in memory.

“Repeal and replace” or “replace and improve” activities on The Hill, though not “business as usual,” won’t necessary slow down data-driven focus areas in healthcare that will continue in 2017.

FDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.

Results from Managed Healthcare Executive’s annual State of the Industry Survey reveal which issues will hit managed healthcare hardest in 2017.

We have a path to ending the HIV epidemic in the United States, but it requires health plans and healthcare purchasers to take a more active role in getting us there.

The US growth rate for spending on medicines is expected to fall in 2016 and beyond, according to new research.

As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.

President-elect Trump named Tom Price and Seema Verma to lead HHS and CMS, respectively. Here’s what you should know about them.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.

CMS is adding, dropping, and expanding payment rules

Hospitals and health systems that treat some of the country’s most vulnerable populations face complex challenges when working to improve population health.

None of Trump’s plans, such as repealing parts of Obamacare or expanding HSAs, will rein in the rising cost of healthcare.

There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study

FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.

Plans and PBMs are finding new ways to rein in pharmacy costs.

Telephonic and personalized diabetes self-education programs which fit into patient’s busy lives will make a greater impact than in-person classes only.

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.